EGFR and neoplasm: We also evaluated the anti-tumor effects of a novel treatment strategy involving the co-administration of Fasudil and an EGFR-TKI (gefitinib) in gefitinib-resistant EGFR-mutation NSCLC using in vivo and vitro models.